These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 9203448)
1. Dexfenfluramine in obese Chinese NIDDM patients. A placebo-controlled investigation of the effects on body weight, glycemic control, and cardiovascular risk factors. Chow CC; Ko GT; Tsang LW; Yeung VT; Chan JC; Cockram CS Diabetes Care; 1997 Jul; 20(7):1122-7. PubMed ID: 9203448 [TBL] [Abstract][Full Text] [Related]
2. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Fujioka K; Seaton TB; Rowe E; Jelinek CA; Raskin P; Lebovitz HE; Weinstein SP; Diabetes Obes Metab; 2000 Jun; 2(3):175-87. PubMed ID: 11220553 [TBL] [Abstract][Full Text] [Related]
3. Benfluorex in obese noninsulin dependent diabetes mellitus patients poorly controlled by insulin: a double blind study versus placebo. Pontiroli AE; Pacchioni M; Piatti PM; Cassisa C; Camisasca R; Pozza G J Clin Endocrinol Metab; 1996 Oct; 81(10):3727-32. PubMed ID: 8855830 [TBL] [Abstract][Full Text] [Related]
4. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005 [TBL] [Abstract][Full Text] [Related]
5. The effects of dexfenfluramine on weight loss and cardiovascular risk factors in female patients with upper and lower body obesity. Ditschuneit HH; Flechtner-Mors M; Adler G J Cardiovasc Risk; 1996 Aug; 3(4):397-403. PubMed ID: 8946272 [TBL] [Abstract][Full Text] [Related]
6. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up. O'Connor HT; Richman RM; Steinbeck KS; Caterson ID Int J Obes Relat Metab Disord; 1995 Mar; 19(3):181-9. PubMed ID: 7780494 [TBL] [Abstract][Full Text] [Related]
7. Pharmacologic induction of weight loss to treat type 2 diabetes. Redmon JB; Raatz SK; Kwong CA; Swanson JE; Thomas W; Bantle JP Diabetes Care; 1999 Jun; 22(6):896-903. PubMed ID: 10372238 [TBL] [Abstract][Full Text] [Related]
8. Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control. Willey KA; Molyneaux LM; Yue DK Diabet Med; 1994; 11(7):701-4. PubMed ID: 7955998 [TBL] [Abstract][Full Text] [Related]
9. Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo. Roger P; Auclair J; Drain P J Diabetes Complications; 1999; 13(2):62-7. PubMed ID: 10432168 [TBL] [Abstract][Full Text] [Related]
10. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. McNulty SJ; Ur E; Williams G; Diabetes Care; 2003 Jan; 26(1):125-31. PubMed ID: 12502668 [TBL] [Abstract][Full Text] [Related]
11. Dexfenfluramine in type II diabetes: effect on weight and diabetes control. Stewart GO; Stein GR; Davis TM; Findlater P Med J Aust; 1993 Feb; 158(3):167-9. PubMed ID: 8450782 [TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. Kaukua JK; Pekkarinen TA; Rissanen AM Int J Obes Relat Metab Disord; 2004 Apr; 28(4):600-5. PubMed ID: 14770192 [TBL] [Abstract][Full Text] [Related]
13. [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group]. Enzi G Ter Arkh; 1997; 69(5):71-5. PubMed ID: 9235665 [TBL] [Abstract][Full Text] [Related]
14. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study. Wang TF; Pei D; Li JC; Tsai WC; Tsai CC; Yao CY; Chang ET; Hsieh MC; Su KY; Kuo SW Int J Clin Pract; 2005 Jul; 59(7):746-50. PubMed ID: 15963197 [TBL] [Abstract][Full Text] [Related]
15. [Pharmacological therapy of obesity]. Pagotto U; Vanuzzo D; Vicennati V; Pasquali R G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755 [TBL] [Abstract][Full Text] [Related]
16. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025 [TBL] [Abstract][Full Text] [Related]
17. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393 [TBL] [Abstract][Full Text] [Related]
18. Dexfenfluramine hydrochloride: an anorexigenic agent. Bever KA; Perry PJ Am J Health Syst Pharm; 1997 Sep; 54(18):2059-72. PubMed ID: 9377205 [TBL] [Abstract][Full Text] [Related]
19. Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women. Flechtner-Mors M; Ditschuneit HH; Yip I; Adler G Am J Clin Nutr; 1998 Apr; 67(4):611-5. PubMed ID: 9537607 [TBL] [Abstract][Full Text] [Related]
20. Dexfenfluramine as an adjunct to a reduced-fat, ad libitum diet: effects on body composition, nutrient intake and cardiovascular risk factors. Swinburn BA; Carmichael HE; Wilson MR Int J Obes Relat Metab Disord; 1996 Nov; 20(11):1033-40. PubMed ID: 8923161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]